May 21 (UPI) --Eli Lilly said its weight loss drug, retatrutide, helped nearly half of participants in a phase 3 trial to lose more than 30% of their weight. Many of the people who lost that much ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
The next generation of glucagonlike peptide 1 (GLP-1) weight-loss drugs has taken another step forward to U.S. Food and Drug Administration approval. In new clinical trial results from the ...
“Gen V,” one of “The Boys” spinoffs series at Amazon Prime Video, is not returning for a third season, Variety has learned. “While we wish we could keep the party going another season at Godolkin, ...
When it comes to deciding on a job, Gen Zers aren’t just thinking about paid time off, return-to-office mandates, or salary negotiations. They’re checking whether a company will cover GLP-1 ...
Burmese pythons have pretty irregular eating habits. One of these giant reptiles can swallow an entire antelope whole and then go up to a year and a half without additional meals. Now, scientists have ...
This is read by an automated voice. Please report any issues or inconsistencies here. We are more connected than ever before, with our high-speed internet, pinging smartphones and ever-updating apps ...
Eli Lilly (LLY) announced on Thursday that a late-stage trial for its next-gen weight loss therapy, retatrutide, reached the primary and all secondary endpoints in adults with type 2 diabetes. Citing ...
(RTTNews) - SCYNEXIS, Inc. (SCYX) has reported its full-year 2025 results, while highlighting progress across its antifungal pipeline, including its next-generation candidate SCY-247 and updates on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results